Xencor | XNCR - Net Income


Xencor reported $-21.73M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
AbbVie USD 3.61B 2.92B Jun/2026
Alnylam Pharmaceuticals USD 164.49M 41.5M Jun/2026
Amgen USD 2.38B 556M Jun/2026
Arrowhead Research USD -132.73M 163.54M Mar/2026
AstraZeneca USD 2.51B 573M Jun/2026
Biogen USD 97.5M 222M Jun/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Cytokinetics USD -198.76M 7.27M Jun/2026
GlaxoSmithKline GBP 435M 1.3B Jun/2026
J&J USD 5.53B 299M Jun/2026
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026
MacroGenics USD -36.77M 22.62M Mar/2026
Merck USD -1.34B 2.9B Jun/2026
Novartis USD 3.26B 108M Jun/2026
Pfizer USD -248M 2.94B Jun/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Xencor USD -21.73M 107.19M Jun/2026